PROQR THERAPEUTICS NV (PRQR) Stock Analyst Ratings
USA - NASDAQ:PRQR - NL0010872495 - Common Stock
2.16 USD
-0.06 (-2.7%)
ChartMill assigns a Buy % Consensus number of 85% to PRQR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 9.18. This target is 325% above the current price.
PRQR was analyzed by 15 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about PRQR.
In the previous month the buy percentage consensus was at a similar level.
PRQR was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-27 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-06-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-29 | Evercore ISI Group | Initiate | Outperform |
| 2025-03-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-12 | Jones Trading | Initiate | Buy |
| 2024-12-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-12 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-12-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-29 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2024-05-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-18 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-03-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-08 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2023-11-08 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-09-18 | Citigroup | Maintains | Buy -> Buy |
| 2023-08-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-04 | Chardan Capital | Reiterate | Neutral -> Neutral |
| 2023-05-17 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-05-17 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-05-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-30 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-30 | HC Wainwright & Co. | Maintains | Buy |
| 2022-12-23 | Raymond James | Maintains | Outperform |
PROQR THERAPEUTICS NV / PRQR FAQ
What is the average price target for PROQR THERAPEUTICS NV (PRQR) stock?
15 analysts have analysed PRQR and the average price target is 9.18 USD. This implies a price increase of 325% is expected in the next year compared to the current price of 2.16.
What is the consensus rating for PRQR stock?
The consensus rating for PROQR THERAPEUTICS NV (PRQR) is 85.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.